Jungi W F
Wien Klin Wochenschr. 1984 Jun 22;96(13):486-92.
Postoperative adjuvant chemotherapy prolongs the recurrence-free interval and, probably, overall survival in patients with surgically-treated, node-positive breast cancer. Composition, dosage, timing and duration of cytostatic treatment are not yet standardized. Among node-negative patients those with a relatively high risk of recurrence (receptor negative) should also be given adjuvant chemotherapy. Combination with endocrine treatment and/or radiotherapy merits further investigation. We need more large, well-designed controlled clinical studies to answer the numerous unsolved questions on this subject.
术后辅助化疗可延长手术治疗的淋巴结阳性乳腺癌患者的无复发生存期,并可能延长总生存期。细胞毒性治疗的组成、剂量、时机和持续时间尚未标准化。在淋巴结阴性患者中,复发风险相对较高(受体阴性)的患者也应接受辅助化疗。与内分泌治疗和/或放疗联合应用值得进一步研究。我们需要更多大型、设计良好的对照临床研究来回答关于这个主题的众多未解决问题。